News

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery.

The NYU Grossman School of Medicine launches a Journal Club series with Ophthalmology Times, featuring expert faculty discussions on ophthalmology research to enhance clinical practice and trainee education.

Trending topics and milestone stories from our year in ophthalmology

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

Did you miss any of our print issues this year? Don’t worry, they are still available online.

The number of patients with retinal vascular diseases is expected to increase over time due to the aging population and lifestyle changes

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

Epioxa is a next-generation corneal cross-linking iLink therapy for the treatment of keratoconus.

Investigators conducted a retrospective clinical audit to determine why patients do not adhere to the guidelines among about 9,000 patients in a practice.

Our top 10 print stories highlight the core content concepts we explored this year

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition

The report details the results of preclinical discovery, engineering and characterization studies evaluating the safety, retinal cell transduction, transgene expression and clinical activity of proprietary evolved intravitreal vector R100 and 4D-150.

Curacle plans to finalize its development strategy, including phase 2b and 3 trials, through a Type C meeting with the US FDA in February of 2025.

The publication is entitled, “Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies.”

Low-level light therapy for dry eye disease and chalazion

In the statement, the board calls attention to a proposal by a committee in the US House of Representatives that would shrink the National Institutes of Health’s (NIH) from 27 institutes into 15 institutes.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

The European Commission will assess the marketing authorisation for Eydenzelt (reference product Eylea)

According to Iridex Corp., the study confirms MicroPulse TLT's sustained safety and efficacy in managing glaucoma, reducing intraocular pressure and medication reliance with minimal complications over 5 years.

Event in San Francisco features a lineup of speakers, latest in glaucoma research and technology.

At the FLORetina Conference in Florence, Italy, John W. Kitchens, of Retina Associates of Kentucky, highlighted strategies to enhance efficiency in retina practices, addressing challenges like staff shortages and rising patient volumes. He emphasized streamlined workflows, advanced diagnostic tools, and enhanced patient communication to optimize care and improve outcomes.

In an interview with Ophthalmology Times, clinical trial investigator Zaina Al-Mohtaseb MD, noted the CLARA Phase 1/2 trial demonstrated the safety, efficacy, and simplicity of corneal endothelial cell injection therapy with a rho kinase inhibitor, offering a less invasive alternative to traditional corneal transplantation for treating corneal edema.